S'abonner

Drug repurposing: Fusidic acid as a potential inhibitor of M. tuberculosis FtsZ polymerization – Insight from DFT calculations, molecular docking and molecular dynamics simulations - 28/07/20

Doi : 10.1016/j.tube.2020.101920 
Olayinka I. Akinpelu a, b, Monsurat M. Lawal a, Hezekiel M. Kumalo a, , Ndumiso N. Mhlongo a,
a School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, 4001, South Africa 
b School of Health Sciences, University of KwaZulu-Natal, Durban, 4001, South Africa 

Corresponding author.∗∗Corresponding author.

Abstract

Filamentous Temperature Sensitive Mutant Z (FtsZ), an important cell division protein in bacteria, has been validated as a potential target for antibiotics development. Citric acid has been found to inhibit the polymerization of Mycobacterium tuberculosis (MTB) FtsZ and several other drugs have been predicted as potential inhibitors through a gene ontology-based drug repurposing approach. An in-depth study on four of the predicted drugs; Fusidic acid (FusA), l-tryptophan, Carbamic acid, and 2-(3-guanidinophenyl)-3-mercaptopropanoic acid, as potential inhibitors of MTB-FtsZ polymerization was conducted using Citric acid as reference compound. The applied in silico methods involve DFT calculations, molecular docking and molecular dynamics simulations. DFT approach was applied to evaluate selectivity and stability properties of the predicted drugs. Calculated parameters including non-linear optical properties, charge distribution and electrostatic potential analyses enabled selectivity prediction of these potential drugs. DFT-based descriptors revealed FusA as the most potent compound, even more reactive than the referenced compound, Citric acid, which is also supported from the molecular docking study. Parameters including MM/PBSA binding free energies, RMSD, RMSF, RoG and hydrogen bond analysis also support FusA as the best potential MTB-FtsZ polymerization inhibitor, that forms a stable complex with the protein and impose greatest level of rigidity to the protein.

Le texte complet de cet article est disponible en PDF.

Graphical abstract

In silico study towards identifying potential anti-tuberculosis drugs.



Image 1

Le texte complet de cet article est disponible en PDF.

Highlights

DFT study of the reactivity and selectivity properties of some potential Filamentous Temperature Sensitive Mutant Z (FtsZ) inhibitors was carried out. The obtained DFT-based chemical parameters proved to be significant in evaluating the selectivity, reactivity and stability of the identified drugs.
Molecular docking analyses of the selected drugs at the active site of MTB-FtsZ showed high binding affinities and all the drugs (except CA), gave binding energy values higher than the reference citric acid with Fusidic acid having the highest binding affinity as revealed from the binding scores.
Molecular dynamics simulations parameters including MM/PBSA binding free energies, RMSD, RMSF, RoG and hydrogen bond analysis also support fusidic acid as the best potential MTB-FtsZ polymerization inhibitor amongst the studied drugs.
Fusidic acid forms the most stable complex with the protein and impose the greatest level of rigidity on it.
The applied in silico methods could be considered and applied to a wide range of bioactive compounds and enzyme—inhibitor systems.

Le texte complet de cet article est disponible en PDF.

Keywords : Drug repurposing, Fusidic acid, Density functional theory calculations, Selectivity and stability prediction, Molecular dynamics simulation, Filamentous temperature sensitive mutant Z, Mycobacterium tuberculosis


Plan


© 2020  Elsevier Ltd. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 121

Article 101920- mars 2020 Retour au numéro
Article précédent Article précédent
  • Phylogenomic assessment of drug-resistant Mycobacterium tuberculosis strains from Beira, Mozambique
  • Evangelina Inacio Namburete, Anzaan Dippenaar, Emilyn Costa Conceição, Cinara Feliciano, Margarida Maria Passeri do Nascimento, Kamila Chagas Peronni, Wilson Araújo Silva, Josefo João Ferro, Lee H. Harrison, Robin Mark Warren, Valdes Roberto Bollela
| Article suivant Article suivant
  • N6-methylated adenine on the target sites of mamA from Mycobacterium bovis BCG enhances macrophage activation by CpG DNA in mice
  • Yumiko Tsukamoto, Toshiki Tamura, Yumi Maeda, Kensuke Miyake, Manabu Ato

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.